Managing cytokine release syndrome in relapsed/refractory multiple myeloma: experience with teclistamab in the MajesTEC-1 study

被引：0
|
作者：
Catamero, Donna [1 ]
Benito, Patricia Blazquez [2 ]
Shenoy, Samantha [3 ]
Chastain, Katherine [4 ]
Kruyswijk, Sandy [5 ]
机构：
[1] Mt Sinai Hlth Syst, New York, NY USA
[2] Univ Hosp Salamanca, Salamanca, Spain
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] Janssen Res & Dev, Raritan, NJ USA
[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NSP-05
引用
收藏
页码：S315 / S316
页数：2
相关论文
共 50 条
  • [11] Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
    Miao, Xin
    Wu, Liviawati S.
    Lin, Shun Xin Wang
    Xu, Yan
    Chen, Yang
    Iwaki, Yuki
    Kobos, Rachel
    Stephenson, Tara
    Kemmerer, Kristy
    Uhlar, Clarissa M.
    Banerjee, Arnob
    Goldberg, Jenna D.
    Trancucci, Danielle
    Apte, Amit
    Verona, Raluca
    Pei, Lixia
    Desai, Rachit
    Hickey, Kathleen
    Su, Yaming
    Ouellet, Daniele
    Samtani, Mahesh N.
    Guo, Yue
    Garfall, Alfred L.
    Krishnan, Amrita
    Usmani, Saad Z.
    Zhou, Honghui
    Girgis, Suzette
    TARGETED ONCOLOGY, 2023, 18 (05) : 667 - 684
  • [12] Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study
    Usmani, Saad Z.
    Karlin, Lionel
    Benboubker, Lotfi
    Nahi, Hareth
    San-Miguel, Jesus
    Trancucci, Danielle
    Qi, Keqin
    Stephenson, Tara
    Puchalt, Alfredo Perales
    Chastain, Katherine
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S477
  • [13] Impact of COVID-19 on Outcomes With Teclistamab in the Phase 1/2 MajesTEC-1 Study in Patients With Relapsed/Refractory Multiple Myeloma
    Usmani, Saad
    Bahlis, Nizar J.
    Costa, Luciano
    Mateos Manteca, Maria-Victoria
    Nooka, Ajay
    Perrot, Aurore
    Thaman, Pragya
    Qi, Keqin
    Uhlar, Clarissa
    Chastain, Katherine
    Doyle, Margaret
    van de Donk, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S93 - S93
  • [14] Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
    van de Donk, Niels W. C. J.
    Bahlis, Nizar
    Costa, Luciano J.
    Mateos, Maria-Victoria
    Nooka, Ajay K.
    Perrot, Aurore
    Garfall, Alfred L.
    Thaman, Pragya
    Qi, Keqin
    Uhlar, Clarissa
    Chastain, Katherine
    Doyle, Margaret
    Usmani, Saad Z.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [15] Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1
    Cai, Zhen
    Xia, Zhongjun
    He, Ai-Li
    Dong, Yu-Jun
    Wang, Yafei
    Liao, Aijun
    Song, Yang
    Song, Juanjuan
    Uhlar, Clarissa
    Chastain, Katherine
    Watkins, Latisha
    Luo, Xinchao
    Huang, Lin
    Niu, Zhuolu
    Carde, Natalia A. Quijano
    Guo, Yue
    Xu, Hongmei
    Verona, Raluca I.
    Zhou, Longen
    Li, Jingyun
    Fu, Weijun
    Niu, Ting
    Du, Juan
    CANCER, 2025, 131 (01)
  • [16] Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
    Usmani, Saad Zafar
    Karlin, Lionel
    Benboubker, Lotfi
    Nahi, Hareth
    San-Miguel, Jesus
    Trancucci, Danielle
    Qi, Keqin
    Stephenson, Tara
    Perales-Puchalt, Alfredo
    Chastain, Katherine
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [17] Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    Rosinol, Laura
    Matous, Jeffrey V.
    Vishwamitra, Deeksha
    Hodin, Caroline
    Stephenson, Tara
    Qi, Keqin
    Zuppa, Athena
    Chastain, Katherine
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S549
  • [18] Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma
    Vishwamitra, Deeksha
    Skerget, Sheri
    Cortes, Diana
    Perova, Tatiana
    Lau, Onsay
    Davis, Cuc
    Guo, Yue
    Miao, Xin
    Stephenson, Tara
    Hodin, Caroline
    Uhlar, Clarissa
    Trancucci, Danielle
    Chastain, Katherine
    Bahlis, Nizar J.
    Van De Donk, Niels W. C. J.
    Verona, Raluca
    BLOOD, 2023, 142
  • [19] Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
    Matous, Jeffrey, V
    van de Donk, Niels W. C. J.
    Oriol, Albert
    Garfall, Alfred L.
    Rodriguez-Otero, Paula
    Chalopin, Thomas
    Dachs, Laura Rosinol
    Uttervall, Katarina
    Mateos, Maria- Victoria
    Trancucci, Danielle
    Carde, Natalia Quijano
    Hodin, Caroline
    Stephenson, Tara
    Zuppa, Athena
    Chastain, Katherine
    Karlin, Lionel
    BLOOD, 2024, 144 : 4749 - 4750
  • [20] Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    Rosinol, Laura
    Matous, Jeffrey V.
    Vishwamitra, Deeksha
    Hodin, Caroline
    Stephenson, Tara
    Qi, Keqin
    Zuppa, Athena
    Chastain, Katherine
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345